Susan Bal

17PUBLICATIONS

73CO-AUTHORS

Haematological tumoursRegenerative medicine (incl. stem cells)Cancer therapy (excl. chemotherapy and radiation therapy)Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Gene and molecular therapy

Get your video featured.

Publish with JoVE

Get your video featured.

Publish with JoVE

Publications (17)

Sort by Publication Date:

|Jul 02, 2026

Real-World Outcomes with BCMA- and GPRC5D-Targeting Bispecific Antibodies in Plasma Cell Leukemia.

|Jun 03, 2026

Arlocabtagene autoleucel-a GPRC5D-targeted CAR T-cell therapy in heavily pretreated relapsed/refractory multiple myeloma.

|Feb 24, 2026

Early mortality with bispecific antibody therapy in RRMM: an IMWG immunotherapy database real-world analysis.

Carlyn Rose Tan, Saad Z Usmani, Andriy Derkach

|Jan 27, 2026

Distinct trajectory of measurable residual disease in t(11;14) myeloma treated with quadruplet therapy.

Susan Bal, Gayathri Ravi, Binod Dhakal

|Jan 06, 2026

Treatment of Multiple Myeloma: ASCO-Ontario Health (Cancer Care Ontario) Living Guideline.

Lisa K Hicks, Hans J Messersmith, Samer Al Hadidi

|Apr 23, 2025

Establishing measurable residual disease trajectories for patients on treatment for newly diagnosed multiple myeloma as benchmark for deployment of T-cell redirection therapy.

Susan Bal, Tylan Magnusson, Gayathri Ravi

Pageof 3

Frequent Collaborators

11 joint publications

Luciano J Costa

Smith Giri

Natalie S Callander

Binod Dhakal

Saurabh Chhabra

Bhagirathbhai R Dholaria

Rahul Banerjee

Shaji Kumar

Parameswaran Hari

Anita D'Souza

Frequent Collaborators

11 joint publications

Luciano J Costa

5 joint publications

Smith Giri

5 joint publications

Natalie S Callander

5 joint publications

Binod Dhakal